Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 02
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Atossa Therapeutics Inc
ATOS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.27
0.32
16.41%
Dern. MÀJ: Oct 2, 7:34 AM
$2.18
0.23
11.79%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Atossa Therapeutics Financials
Atossa Therapeutics (ATOS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share
Benzinga Newsdesk
PRO
Atossa Therapeutics Q1 EPS $(1.11) Misses $(0.94) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.94) by 19.35 percent. This is a 344 percent decrease over losses of $(0.25) per share
Benzinga Newsdesk
PRO
Atossa Therapeutics Q4 EPS $(0.03) Beats $(0.07) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 55.22 percent. This is a 88 percent increase over losses of $(0.25) per share from
Benzinga Newsdesk
PRO
Atossa Therapeutics Q3 EPS $(0.07), Inline
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year.
Benzinga Newsdesk
PRO
Atossa Therapeutics Q2 EPS $(0.07) Misses $(0.06) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 20.69 percent. This is a 40 percent decrease over losses of $(0.05) per share
Benzinga Newsdesk
PRO
Atossa Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
